I

n a rather unusual move, a Wall Street analyst has written an open letter to Gilead Sciences, imploring the drug maker’s executive team to pursue a “meaningful” acquisition before cash flow declines too precipitously.

The missive, which was written by Barclays Bank analyst Geoff Meacham, reflects ongoing investor frustration that the company has yet to pursue a deal to help compensate for declining sales of hepatitis C drugs and disappointing study results for newer medicines.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.